Edit

Sangamo Therapeutics

http://www.sangamo.com/

Last activity: 20.02.2026

Active

Categories: BioTechDevelopmentHealthTechHumanIndustryLivingManagementResearchScienceTechnology

Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy.

Likes

854

Followers

3.44K

Followers

29.27K

Website visits

16.9K /mo.

Mentions

Location: United States, California, Brisbane

Employees: 201-500

Phone: +1 510-970-6000

Founded date: 1995

Twitter

Facebook

Investors 4

Date	Name	Website
13.07.2025	Foresite C...	foresiteca...
-	NeoMed Man...	neomed.net...
-	Ridgeback ...	ridgebackc...
-	Technology...	pivotcente...

Mentions in press and media 18

Date	Title	Description
20.02.2026	Curt Smith: Fighting blood cancer is easier with a group effort	-
15.04.2025	Назад, в генетическое будущее	-
08.03.2021	Editas, Intellia: After Big Sell Off, Is it Time To Buy Gene Editing Stocks?	BRAZIL - 2021/02/18: In this photo illustration an Editas Medicine logo seen displayed on a ... [+] smartphone with the stock market graphic in the background. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images)...
11.02.2021	Vertex, Intellia Therapeutics: Gene Editing Stocks To Watch	BRAZIL - 2020/01/13: In this photo illustration the Vertex Pharmaceuticals logo is seen displayed on ... [+] a smartphone. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Ima...
28.01.2021	Intellia, Editas: How Are Gene Editing Stocks Faring?	Gene-editing technology is used to insert, edit, or delete a gene from an organism’s genome, and shows promise in treating medical conditions ranging from cancer to rare genetic conditions. Our indicative theme on Gene Editing Stocks has re...
11.01.2021	CRISPR, Editas, Intellia: Gene Editing Stocks To Play The Next Revolution In Medicine	BRAZIL - 2020/10/29: In this photo illustration the CRISPR Therapeutics logo seen displayed on a ... [+] smartphone. (Photo Illustration by Rafael Henrique/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images
10.05.2018	Should You Be Using CRISPR for Your Ag Business?	Updated reference to Pairwise with correction regarding agreement with Monsanto Editor’s Note: Vonnie Estes was the 2017 recipient of Rosalind Franklin award for leadership in Biotechnology. She is an agtech innovation consultant with a p...
30.10.2017	Gene editing remains early stage, but Big Pharma has taken notice	In its recent report, titled Gene Editing: The Next Breakthrough in Regenerative Medicine, Informa Pharma Intelligence answers those questions with a focus on three major existing technologies: CRISPR/Cas9, zinc-finger nucleases (ZFNs), and...
10.05.2017	Pfizer and Sangamo ink a $545M hemophilia-gene therapy deal	In return for global commercialization rights, Pfizer will pay $70 million upfront and up to $475 million in milestone payments that encourage both the commercialization of SB-525 and the development of new hemophilia A therapies. With fres...
25.10.2016	CRISPR identifies genes that might be targeted to hobble HIV infection	Whether or not CRISPR/Cas9 genome editing can create superheroes as depicted on a new Netflix show, what it’s indisputably good at is this: editing a lot of genes really, really fast. In research published Tuesday in Cell Reports, scientist...
18.07.2016	Do CRISPR enthusiasts have their head in the sand about the safety of gene editing?	WASHINGTON — At scientific meetings on genome-editing, you’d expect researchers to show pretty slides of the ribbony 3-D structure of the CRISPR-Cas9 molecules neatly snipping out disease-causing genes in order to, everyone hopes, cure illn...
09.06.2016	CRISPR/Cas9 already is a revolution in molecular biology	As you might expect given the excitement, the last 12-24 months have seen huge upswing in popular interest in CRISPR as well as in the scientific literature (see chart below). Jennifer Doudna and Emmanuelle Charpentier’s groups published th...
11.08.2015	CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape	But that’s already turned quickly on its head. Confidence is growing in the technology, as evidenced by the title of a fantastic Wired article: “Easy DNA Editing Will Remake the World. Buckle Up.” And the broader scientific community is now...
-	Gene editing remains early stage, but Big Pharma has taken notice	The field of gene editing is moving fast. In late October, two new papers described technologies that allow for the precise editing of individual DNA bases — an A to a T, a C to a G — and, separately, a mechanism for genetically editing RNA...
-	Pfizer and Sangamo ink a $545M hemophilia-gene therapy deal	Sangamo Therapeutics has lofty aims for its gene therapy programs — but at least one Big Pharma company thinks they’re achievable. On Wednesday, the Richmond, California-based company announced a global collaboration and licensing agreement...
-	CRISPR/Cas9 already is a revolution in molecular biology	CRISPR/Cas9 genome editing has captured the attention of the popular media, scientific community and the investment world: the promise of going into a cell and precisely making changes in their genetic code to cure them of illness is certai...
-	Advances in genomic engineering seek to transform the treatment of neuropathic pain by targeting Nav1.7	As researchers continue to seek new treatments for neuropathic pain, advances in genomics are presenting new methods for modulating biological pathways that play an important role in this complex condition. This confluence of the new and th...
-	CRISPR: Editas’ $120M proves it isn’t a bunch of hype. Here are 6 more biotechs shaping CRISPR landscape	CRISPR/Cas9 gene editing has zoomed to the forefront of the biotech investment scape in the past year — punctuated this week by Editas Medicine‘s impressive $120 million fundraise. Looks like it’s no longer hype — there’s solid funding to p...

Sangamo Therapeutics

Investors 4

Mentions in press and media 18

Reviews 0